ABEONA THERAPEUTICS INC. (ABEO) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $13.33M; Long-term Debt, Excluding Current MaturitiesUSD $1.66M; Long-term DebtUSD $14.99M; Long-Term Debt, Maturity, Year OneUSD $7.78M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $13.33M; Long-term Debt, Excluding Current MaturitiesUSD $4.75M; Long-term DebtUSD $18.09M; Long-Term Debt, Maturity, Year OneUSD $7.78M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $12.22M; Long-term Debt, Excluding Current MaturitiesUSD $7.81M; Long-term DebtUSD $20.04M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $12.22M.
ABEONA THERAPEUTICS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Short-term Debt USD | Secured Debt, Current USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Periodic Payment, Principal USD | Debt Instrument, Increase, Accrued Interest USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $13.33M | $1.66M | $14.99M | $7.78M | (m) | (m) | $6.67M | $14.44M | $16.00M | $319.00K | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $13.33M | $4.75M | $18.09M | $7.78M | (m) | (m) | $10.00M | $17.78M | $18.70M | $484.00K | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $12.22M | $7.81M | $20.04M | (m) | (m) | (m) | (m) | $20.00M | $21.20M | $676.00K | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $12.22M | $7.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $8.89M | $10.86M | $19.75M | $12.22M | $7.78M | (m) | (m) | $20.00M | $22.00M | $874.00K | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $5.56M | $14.01M | $19.56M | $12.22M | $7.78M | (m) | (m) | $20.00M | $21.90M | $983.00K | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $8.15M | $11.14M | $19.29M | $8.89M | $5.18M | (m) | $5.93M | $20.00M | $24.30M | $1.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $5.93M | $13.04M | $18.96M | (m) | (m) | (m) | (m) | $20.00M | $24.70M | $1.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $5.93M | $8.89M | $5.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $4.44M | $14.21M | $18.65M | $6.67M | $8.89M | $4.44M | (m) | $20.00M | (m) | $1.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $2.22M | $16.13M | $18.36M | $6.67M | $8.89M | $4.44M | (m) | $20.00M | (m) | $1.81M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $18.08M | $18.08M | $6.67M | $8.89M | $4.44M | (m) | $20.00M | (m) | $2.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $28.00M | 12 month · $3.50M |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $28.00M | 9 month · $2.10M |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $28.00M | 6 month · $800.00K |
| 2020-05-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1.00% | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $400.00K | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $250.00K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.75M | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.75M | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.75M | 12.00% | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |